Shane Michael Woolever, D.O. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 146 W Spruce St, Sault Sainte Marie, MI 49783 Phone: 906-635-5100 Fax: 906-635-1143 |
News Archive
Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced results of a survey conducted during its recent webinar entitled "Designing and Delivering an eClinical Product Suite."
Imagine harnessing the proliferating power of cancer cells to treat spinal cord injuries and restore function following brain damage. It's an idea that University of Massachusetts Amherst biomedical engineer Chase Cornelison has been exploring in recent years.
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
A molecule designed by a Purdue University researcher could lead to the first drug treatment for Alzheimer's disease.
› Verified 2 days ago